Page 854 - Withrow and MacEwen's Small Animal Clinical Oncology, 6th Edition

832 Index

Novel therapeutics, for intracranial tumors, Odontogenic tumors, 447, 448f Oral squamous cell carcinoma (SCC),
665 OHE. see Ovariohysterectomy Oral tumors, 432
environmental tobacco smoke and, 14, 92
Oil Red O stain, 71t
NSAID. see Nonsteroidal antiinflammatory
VetBooks.ir Nuclear division, 36 Oligoastrocytic tumors, 658t chemotherapy for, 440
drug
diagnosis for, 436
Oligodendroglial tumors, 658t
Nuclear export, 272 Oligodendroglioma, 666t diagnostic techniques and workup for,
Nuclear protein ONCEPT vaccine, 239–240 436–437
gene expression and, 42–43 development/approval of use, 345 biopsy in, 436
types of, 42t Oncogene, 41, 41t distant metastasis, clinical staging of, 437
Nuclear scintigraphy, 118 activation of, 42–43 history and clinical signs of, 435
Nucleolar size, 69t chromosomal translocation, 42 incidence and risk factors of, 432
Nucleophosmin gene (NPMI), 4–5 gene amplification, 42 local tumor, clinical staging of, 436, 436f
Nucleoside transporter, 184 methods of, 40f pain caused by, 287t
Null cell lymphoma, 72t–73t point mutations, 42–43 pathology and natural behavior of,
Nutritional assessment, 302–304 viral insertions, 43 432–435
Nutritional management, 300 cancer and, 41 acanthomatous ameloblastoma, 435
antioxidants/supplements for, 309–310 functional classification of, 42t fibrosarcoma, 434–435, 435f
assisted enteral support for, 304–305 proto-oncogene conversion to, 42 malignant melanoma, 432, 434f
coax feeding/appetite stimulation and, 304 role of, 4–5, 25 osteosarcoma, 435
dietary substrate effects, 301 Oncogenic mutation, identification of, 347 squamous cell carcinoma as, 432–434,
fish-based, omega-3 fatty acid-enhanced Oncology 434f–435f
diet as, 308–309 cytopathology in, 126–145 prognosis for, 440–445
during hospitalization, 304 imaging in, 113–125 fibrosarcoma, 444
implementing a plan for, 302–304 integrative, 330–339 malignant melanoma, 440–442
risk factors for cancer, 301–302 approaches in, 331–336 osteosarcoma, 444
substrates for, 306–308 definition of, 330–331 radiation therapy for, 437–440
vitamins and minerals for, 309 goals of, 330 regional lymph node, clinical staging of,
integrative medicine into, 330 436–437, 438f
O interventional, 174–181 staging for, 434t
Obesity molecular diagnosis of, 146 summary of, 433t
cancer development and, 302 precision medicine differs from current, surgery for, 437, 439t, 440f
observational studies for, 87t–91t 154–155 mandibulectomies, 439t
Observational study surgical, 164–173 maxillectomies, 439t
case-control study design as, 85–86 Oncolytic viruses, 237 treatment for, 437–440
definition of, 82t Oncovirus, 252t Oral/lip melanoma, 68t
findings from, 92 Onyx 015 vector, 254, 254f Orbital neoplasia, 683
environmental exposures, 92 Opioid, 295 Orbital tumors, 675, 683–684
systematic error and, 86 Optic nerve tumors, 683–684 diagnostic techniques and workup for,
types of, 87t–91t Oral cavity, cancer of, 445–448 683–684, 684f
use of, 86 comparative aspects of, 448 history and clinical signs of, 683
Octreotide lingual, 445–446, 446f incidence and risk factors for, 683
for canine insulinoma, 584 lingual tumors, 445–446 pathology and natural behavior of, 683
for feline acromegaly, 571 multilobular osteochondrosarcoma, 447, prognosis for, 684
Ocular melanosis of Cairn, 679 447f therapy for, 684
Ocular papilloma odontogenic tumors, 447 Organ transplantation, 353–354
clinical features of, 21 tonsillar squamous cell carcinoma, 445, 446f Organ tumor
view of, 20f undifferentiated malignancy of young dogs, adrenal cortical/medullary, 137
Ocular squamous cell carcinoma, 675 447 biliary, 135
Ocular tumors, 675–687 viral papillomatosis, 432 carcinoids, 137
cancer therapeutic modalities effects on, Oral fludrocortisone suppression test, in feline chemodectomas, 137
684 adrenocortical tumors, 573 endocrine and neuroendocrine, 136
comparative aspects of, 684–685 Oral ketamine, 295–296 exocrine pancreas, 135
eyelids, third eyelid, conjunctiva, and ocular Oral melanoma gastrointestinal, 136
surface tumors, 675–678 breed predilection and differentials for, 367 hepatocellular, 135
limbal (epibulbar) melanomas, 678, 678f computed tomography of, 375f insulinoma, 137
primary, 678–684 radiation therapy for, 370–374, 373f–374f nasal carcinoma and adenocarcinoma, 136
Ocular viral papilloma with chemotherapy, 374–376 parathyroid, 137
incidence of, 675 published studies for, 372t–373t pulmonary carcinoma/adenocarcinoma,
pathology and behavior of, 675 staging for, 368–369 135
Odds ratio (OR) tumor-node-metastasis of, 368f renal carcinoma, 135
calculation of, 86 survival rate with, 368, 374 thymoma and thymic carcinoma, 135–136
interpretation of, 86, 86t treatment of, surgical aspects, 369–370 thyroid carcinoma, 137